Iovance Biotherapeutics, Inc. (IOVA)财务
NASDAQ · Healthcare · Biotechnology · 员工975人 · CEO Frederick G. Vogt
- 股价
- $8.48 -11.30%
- 市值
- $38.4亿
- 企业价值
- $37.8亿
- 最近财报
- Q2 '26 2026-08-06提交
- 下次财报
- 2026-11-05 EPS预期 -$0.08
营收(TTM)$3.25亿+34.5% 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)-91.1%+78.9 百分点 对比去年同期营业利润 -$2.96亿
净利润(TTM)-$2.9亿+25.7% 对比去年同期税后,含营业外收益
自由现金流(TTM)-$2.96亿+8.4% 对比去年同期资本支出 $3220万
稀释EPS(TTM)-$0.73+40.7% 对比去年同期最近4个季度之和
净现金$2.52亿+1.5% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $38.4亿 EV $37.8亿
- 营收
- $3.25亿 过去12个月
- 营收增速
- +57% FY2026年一致预期
- 净利润率
- -89.1% 净利润 / 营收,TTM
- P/E
- -11.6× 预期 -19.1×(FY2026)
- P/S
- 11.8× 股价 / 营收,TTM
- EV / EBITDA
- -15.0× TTM
- 自由现金流
- -$2.96亿 过去12个月
- 净利润
- -$2.9亿 过去12个月
- 营收预期
- $4.15亿 FY2026年一致预期
- 盈利
- 2026-11-05 营收预期 $1.16亿
- 股息
- – 无股息
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-08-06):营收超预期13.1%,EPS 超预期17.6%营收$9930万,预期$8780万(+13.1%);EPS -$0.11,预期-$0.13(+17.6%)。
- 营收增长加速:同比65.7%Q2 '26营收$9930万,此前四个季度的平均值为42.6%。
- 营业利润率-91.1%(TTM),较去年同期+78.9 百分点营收增长34.5%,营业利润增长27.9%。
- 资本支出占营收的9.9%(去年为8.3%)最近4个季度投入$3220万(同比+60.0%)。自由现金流-$2.96亿。
- 稀释股数一年内增加34.6%Q2 '26稀释股数4.5亿,一年前为3.35亿。
- 净现金 $2.52亿现金 + 短期投资 $2.98亿,含租赁债务 $4600万;一年前净现金 $2.48亿。
上一季度:Q2 '26
截至2026-06-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q2 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $9930万 | $6000万 | +65.7% |
| 毛利率 | 56.1% | 18.5% | +37.6 百分点 |
| 营业利润 | -$5190万 | -$1.14亿 | +54.4% |
| 营业利润率 | -52.3% | -189.8% | +137.5 百分点 |
| 净利润 | -$4730万 | -$1.12亿 | +57.6% |
| 稀释EPS | -$0.11 | -$0.33 | +66.7% |
| 经营现金流 | -$6080万 | -$6740万 | +9.8% |
| 资本支出 | $544万 | $746万 | -27.1% |
| 自由现金流 | -$6630万 | -$7490万 | +11.5% |
| R&D | $5890万 | $7790万 | -24.5% |
| 股权激励费用 | $1170万 | $1490万 | -21.5% |
实际 vs 一致预期
2026-08-06| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| 营收 | $9930万 | $8780万 | +13.1% |
| EPS(一致预期口径) | -$0.11 | -$0.13 | +17.6% |
来自2026-08-06发布的Q2 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q3 '23 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Product | $50万 | – | 100.0% | – | – |
按地区划分的营收
占总额比例| 分部 | Q3 '23 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| United States | $9900万 | +68.9% | 99.7% | $3.21亿 | +19.8% | |
| Non-US | $34.6万 | -74.3% | 0.3% | $364万 | -18.7% |
利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- -$2.64亿
- 资本支出
- -$3220万
- 股票回购
- $0
- 股息
- $0
- 收购
- $0
- 债务净发行
- $0
- 股权激励费用
- $4670万
- 自由现金流
- -$2.96亿
- 股东回报 / FCF
- 0.0%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | -11.6× | – | – |
| EV / EBITDA | -15.0× | – | – |
| EV / 营收 | 11.6× | 530.3× 5年中的3年 | 3.3× – 1,574.9× |
| 股价 / FCF | -13.0× | – | – |
| 股价 / 净资产 | 5.2× | 2.9× | 1.4× – 4.7× |
| FCF收益率 | -7.7% | -22.3% | -34.5% – -9.1% |
| 投入资本回报率 | -36.0% | -57.0% | -68.2% – -49.0% |
| 净资产收益率 | -40.5% | -63.7% | -79.2% – -52.4% |
分析师
一致目标价 $13.44 (+58.5%)
区间 $5.00 – $20.00 · 评级 Buy
强烈买入0
买入15
持有6
卖出0
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $4.15亿 | +57.4% | -$0.44 | +59.3% | -19.1× | 6 |
| FY2027 | $5.94亿 | +43.1% | -$0.17 | +61.7% | -49.9× | 6 |
| FY2028 | $8.82亿 | +48.5% | $0.24 | +241.7% | 35.2× | 4 |
| FY2029 | $11.1亿 | +26.0% | $0.27 | +10.0% | 32.0× | 1 |
| FY2030 | $14.2亿 | +27.6% | $0.52 | +96.2% | 16.3× | 1 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Iovance Biotherapeutics, Inc.在近期10-Q / 10-K文件中标记的全部179项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $2620万 | $3200万 | -18.1% | $2220万 | $2750万 | -19.4% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $1.02亿 | $5990万 | +70.4% | $8240万 | $6930万 | +18.9% |
| Accretion (Amortization) of Discounts and Premiums, Investments | $141万 | $200万 | -29.5% | $720万 | $1030万 | -29.8% |
| Accrued Employee Benefits, Current | $3070万 | $2430万 | +26.3% | $3380万 | $3190万 | +5.9% |
| Accrued Liabilities and Other Liabilities | $7800万 | $8910万 | -12.5% | $1.11亿 | $8190万 | +35.7% |
| Accrued Liabilities, Current | $7800万 | $8910万 | -12.5% | $1.11亿 | $8190万 | +35.7% |
| Accrued Professional Fees, Current | $154万 | $204万 | -24.6% | $142万 | $247万 | -42.6% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $5640万 | $4210万 | +33.9% | $4880万 | $3600万 | +35.4% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $1310万 | $2090万 | -37.3% | $1640万 | -$105万 | +1,671.7% |
| Additional Paid in Capital | $36.2亿 | $32.9亿 | +10.2% | $34.6亿 | $31亿 | +11.7% |
| Amortization of Intangible Assets | $572万 | $570万 | +0.3% | $2310万 | $2640万 | -12.5% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | -139万 | -34.9万 | -299.5% | 2970万 | 3090万 | -4.1% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $1190万 | $1450万 | -17.9% | $6090万 | $1.11亿 | -45.1% |
| Assets | $9.16亿 | $9.07亿 | +0.9% | $9.13亿 | $9.1亿 | +0.3% |
| Assets, Current | $4.64亿 | $4.23亿 | +9.9% | $4.43亿 | $4.57亿 | -3.1% |
| Cash and Cash Equivalents, at Carrying Value | $1.11亿 | $1.32亿 | -16.4% | $1.63亿 | $1.16亿 | +41.0% |
| Cash Equivalents, at Carrying Value | $6110万 | $8140万 | -24.9% | $6050万 | $6140万 | -1.6% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $1.17亿 | $1.38亿 | -15.6% | $1.69亿 | $1.22亿 | +38.5% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$8570万 | -$3960万 | -116.3% | $4700万 | -$5930万 | +179.3% |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | 0.0% | $0.00 | $0.00 | 0.0% |
| Common Stock, Shares Authorized | 6.5亿 | 5亿 | +30.0% | 5亿 | 5亿 | 0.0% |
| Common Stock, Shares, Issued | 4.53亿 | 3.42亿 | +32.5% | 4.12亿 | 3.05亿 | +35.0% |
| Common Stock, Shares, Outstanding | 4.53亿 | 3.42亿 | +32.5% | 4.12亿 | 3.05亿 | +35.0% |
| Common Stock, Value, Issued | $1.9万 | $1.4万 | +35.7% | $1.7万 | $1.3万 | +30.8% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$4690万 | -$9710万 | +51.7% | -$3.73亿 | -$3.76亿 | +0.6% |
| Conversion of Stock, Amount Converted | $02025-12-31 | – | – | $1000 | – | – |
| Cost of Revenue | $4360万 | $4890万 | -10.8% | $1.73亿 | $9320万 | +85.7% |
| Costs and Expenses | $1.51亿 | $1.74亿 | -13.0% | $6.67亿 | $5.59亿 | +19.2% |
| Debt Securities, Available-for-sale | $2.48亿 | $2.5亿 | -0.8% | $1.94亿 | $2.7亿 | -27.9% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $10002026-03-31 | $7000 | -85.7% | $6.3万 | $11.7万 | -46.2% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $7.4万 | $2.4万 | +208.3% | $91万2022-12-31 | $61.2万 | +48.7% |
| Debt Securities, Available-for-sale, Amortized Cost | $2.48亿 | $2.5亿 | -0.8% | $1.94亿 | $2.69亿 | -27.9% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions | 0.0% | 0.0% | – | – | – | – |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions | 0 item2025-12-31 | – | – | 0 item | – | – |
| Debt Securities, Available-for-sale, Current | $1.87亿 | $1.69亿 | +10.8% | $1.34亿 | $2.08亿 | -35.7% |
| Debt Securities, Available-for-sale, Unrealized Loss | $0 | $0 | – | $0 | $0 | – |
| Deferred Income Tax Expense (Benefit) | -$137万 | $199万 | -169.1% | -$207万 | -$283万 | +26.8% |
| Deferred Income Tax Liabilities, Net | $2930万 | $3470万 | -15.5% | $3180万 | $3230万 | -1.5% |
| Deferred Tax Assets, Gross | $7.06亿2025-12-31 | $5.75亿 | +23.0% | $7.06亿 | $5.75亿 | +23.0% |
| Deferred Tax Assets, Net of Valuation Allowance | $1900万2025-12-31 | $1690万 | +12.1% | $1900万 | $1690万 | +12.1% |
| Deferred Tax Assets, Operating Loss Carryforwards | $4.16亿2025-12-31 | $3.03亿 | +37.4% | $4.16亿 | $3.03亿 | +37.4% |
| Deferred Tax Assets, Other | $222万2025-12-31 | $0 | – | $222万 | $0 | – |
| Deferred Tax Assets, Tax Credit Carryforwards | $6520万2025-12-31 | $6690万 | -2.5% | $6520万 | $6690万 | -2.5% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $4130万2025-12-31 | $4090万 | +0.9% | $4130万 | $4090万 | +0.9% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals | $1890万2025-12-31 | $1150万 | +64.2% | $1890万 | $1150万 | +64.2% |
| Deferred Tax Assets, Valuation Allowance | $6.88亿2025-12-31 | $5.58亿 | +23.3% | $6.88亿 | $5.58亿 | +23.3% |
| Deferred Tax Liabilities, Net | $3180万2025-12-31 | $3230万 | -1.5% | $3180万 | $3230万 | -1.5% |
| Deferred Tax Liabilities, Other | $17.9万2025-12-31 | $0 | – | $17.9万 | $0 | – |
| Defined Contribution Plan, Cost | – | – | – | $640万 | $470万 | +36.2% |
| Depreciation, Depletion and Amortization | $378万 | $340万 | +11.3% | $1290万 | $1130万 | +14.3% |
| Depreciation, Depletion and Amortization, Nonproduction | $950万 | $935万 | +1.6% | $3590万 | $3760万 | -4.4% |
| Earnings Per Share, Basic | -$0.11 | -$0.33 | +66.7% | -$1.09 | -$1.28 | +14.8% |
| Earnings Per Share, Diluted | -$0.11 | -$0.33 | +66.7% | -$1.09 | -$1.28 | +14.8% |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | -$12.4万 | $73.9万 | -116.8% | $114万 | -$54.1万 | +311.5% |
| Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | – | – | – | -$8250万 | – | – |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 0.0% | 0.0% | – | 21.0% | 21.0% | 0.0% |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | – | – | – | $5850万 | – | – |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | – | – | – | -15.0% | -29.0% | +48.3% |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | – | – | – | $178万 | – | – |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | – | – | – | 0.0% | – | – |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标和预期均根据公司文件标准化。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
数据截至 2026-11-02